Repligen
RGEN • NASDAQ
Repligen is a medical - instruments & supplies company in the healthcare sector trading on NASDAQ, led by CEO Olivier Loeillot, with a market cap of $6.2B.
CEOOlivier Loeillot
Next Earnings
Upcoming earnings announcement for Repligen
Date
Tuesday, April 28, 2026 (in 3 weeks)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.38
Revenue Estimate
$191.6M
Earnings History
Past 12 earnings reports for Repligen
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Q4 2025 | $0.49Est: $0.44 | +11.4% | $197.9MEst: $192.2M | +3.0% |  10-K |
| Oct 28, 2025 | Q3 2025 | $0.46Est: $0.42 | +9.5% | $188.8MEst: $181.5M | +4.0% | 10-Q |
| Jul 29, 2025 | Q2 2025 | $0.37Est: $0.39 | -5.1% | $182.0MEst: $175.5M | +3.7% | 10-Q |
| Apr 29, 2025 | Q1 2025 | $0.39Est: $0.35 | +11.4% | $169.2MEst: $163.8M | +3.3% | 10-Q |
| Feb 20, 2025 | Q4 2024 | $0.44Est: $0.41 | +7.3% | $167.5MEst: $167.6M | -0.0% | 10-K |
| Nov 12, 2024 | Q3 2024 | $0.43Est: $0.33 | +30.3% | $154.9MEst: $153.2M | +1.1% | 10-Q/A |
| Jul 30, 2024 | Q2 2024 | $0.33Est: $0.33 | 0.0% | $154.1MEst: $154.1M | -0.0% | — |
| May 1, 2024 | Q1 2024 | $0.28Est: $0.30 | -6.7% | $151.3MEst: $150.1M | +0.9% | — |
| Feb 21, 2024 | Q4 2023 | $0.33Est: $0.33 | 0.0% | $155.7MEst: $155.4M | +0.2% | — |
| Oct 31, 2023 | Q3 2023 | $0.23Est: $0.17 | +35.3% | $141.2MEst: $140.6M | +0.4% | — |
| Aug 2, 2023 | Q2 2023 | $0.53Est: $0.49 | +8.2% | $159.2MEst: $167.2M | -4.8% | — |
| May 2, 2023 | Q1 2023 | $0.64Est: $0.59 | +8.5% | $182.7MEst: $181.4M | +0.7% | — |